Suciu-Foca N, Herter F P, Buda J A, Reemtsma K
Oncology. 1975;31(3-4):125-32. doi: 10.1159/000225015.
The PHA and MLC reactivity of lymphocytes from patients with cancer, SLE or renal allografts was comparatively tested in the presence of autologous and of normal homologous serum. Sera from patients with advanced cancer, active SLE or chronic allograft rejection strongly inhibited the MLC reactivity of autologous lymphocytes. It is suggested that serum inhibitory factors might be antibodies which are directed against modified antigenic determinants of the major histocompatibility complex, and are capable of blocking T lymphocyte receptors.
对癌症、系统性红斑狼疮（SLE）患者或肾移植受者的淋巴细胞，在自体血清和正常同源血清存在的情况下，比较检测了其对PHA（植物血凝素）和MLC（混合淋巴细胞培养）的反应性。晚期癌症、活动性SLE或慢性移植排斥患者的血清强烈抑制自体淋巴细胞的MLC反应性。提示血清抑制因子可能是针对主要组织相容性复合体修饰抗原决定簇的抗体，并且能够阻断T淋巴细胞受体。
